HIV drug fails to prevent COVID in High-Risk healthcare workers
NCT ID NCT04405271
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tested whether a daily pill (TAF/FTC), normally used for HIV, could prevent COVID-19 in healthcare workers at high risk of exposure. About 1,378 participants were randomly assigned to receive the drug or a placebo. The trial was terminated early, and the results did not show a clear benefit for preventing COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sociedad Argentina de Infectología, A. J. Carranza 974
Buenos Aires, Buenos Aires F.D., C1085, Argentina
Conditions
Explore the condition pages connected to this study.